Samsung begun to acquire the biosimilar of ‘Enbrel’ in Europe
Samsung has pushed ahead to acquire the European approval of the ‘Enbrel’biosmilar.
Samsung Bioepis announced that the European Medicines Agency (EMA) completed reviewing the application for the sale approval of the Enbrel (etanercept) biosimilar(hereinafter referring to SB4) and started to eval...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
